Metallothionein - Immunohistochemical Cancer Biomarker: A
Meta-Analysis

J 2014

Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis

GUMULEC, Jaromír; Martina RAUDENSKÁ; Vojtěch ADAM; René KIZEK; Michal MASAŘÍK et al.

Základní údaje

Originální název

Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis

Autoři

GUMULEC, Jaromír; Martina RAUDENSKÁ ; Vojtěch ADAM; René KIZEK a Michal MASAŘÍK

Vydání

PLOS ONE, USA, PUBLIC LIBRARY SCIENCE, 2014, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.234

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00080137

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

SQUAMOUS-CELL CARCINOMA; PAPILLARY THYROID-CARCINOMA; PROSTATE-SPECIFIC ANTIGEN; PRIMARY BREAST CARCINOMAS; HUMAN BLADDER-CANCER; HEPATOCELLULAR-CARCINOMA; OVARIAN-TUMORS; PROGNOSTIC-SIGNIFICANCE; DRUG-RESISTANCE; CLINICOPATHOLOGICAL SIGNIFICANCE

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 9. 2014 08:38, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Metallothionein (MT) has been extensively investigated as a molecular marker of various types of cancer. In spite of the fact that numerous reviews have been published in this field, no meta-analytical approach has been performed. Therefore, results of to-date immunohistochemistry-based studies were summarized using meta-analysis in this review. Web of science, PubMed, Embase and CENTRAL databases were searched (up to April 30, 2013) and the eligibility of individual studies and heterogeneity among the studies was assessed. Random and fixed effects model meta-analysis was employed depending on the heterogeneity, and publication bias was evaluated using funnel plots and Egger's tests. A total of 77 studies were included with 8,015 tissue samples (4,631 cases and 3,384 controls). A significantly positive association between MT staining and tumors (vs. healthy tissues) was observed in head and neck (odds ratio, OR 9.95; 95% CI 5.82-17.03) and ovarian tumors (OR 7.83; 1.09-56.29), and a negative association was ascertained in liver tumors (OR 0.10; 0.03-0.30). No significant associations were identified in breast, colorectal, prostate, thyroid, stomach, bladder, kidney, gallbladder, and uterine cancers and in melanoma. While no associations were identified between MT and tumor staging, a positive association was identified with the tumor grade (OR 1.58; 1.08-2.30). In particular, strong associations were observed in breast, ovarian, uterine and prostate cancers. Borderline significant association of metastatic status and MT staining were determined (OR 1.59; 1.03-2.46), particularly in esophageal cancer. Additionally, a significant association between the patient prognosis and MT staining was also demonstrated (hazard ratio 2.04; 1.47-2.81). However, a high degree of inconsistence was observed in several tumor types, including colorectal, kidney and prostate cancer. Despite the ambiguity in some tumor types, conclusive results are provided in the tumors of head and neck, ovary and liver and in relation to the tumor grade and patient survival.

Návaznosti

NT14337, projekt VaV

Název: Studium a charakterizace primárních nádorových buněčných linií spinocelulárních karcinomů v oblasti hlavy a krku a jejich maligní potenciál.

Investor: Ministerstvo zdravotnictví ČR, Studium a charakterizace primárních nádorových buněčných linií spinocelulárních karcinomů v oblasti hlavy a krku a jejich maligní potenciál.

Citovat

GUMULEC, Jaromír; Martina RAUDENSKÁ; Vojtěch ADAM; René KIZEK a Michal MASAŘÍK. Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis. PLOS ONE. USA: PUBLIC LIBRARY SCIENCE, 2014, roč. 9, č. 1, s. "e85346", 14 s. ISSN 1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0085346.

@article{1187238,
   author = {Gumulec, Jaromír and Raudenská, Martina and Adam, Vojtěch and Kizek, René and Masařík, Michal},
   article_location = {USA},
   article_number = {1},
   doi = {https://doi.org/10.1371/journal.pone.0085346},
   keywords = {SQUAMOUS-CELL CARCINOMA; PAPILLARY THYROID-CARCINOMA; PROSTATE-SPECIFIC ANTIGEN; PRIMARY BREAST CARCINOMAS; HUMAN BLADDER-CANCER; HEPATOCELLULAR-CARCINOMA; OVARIAN-TUMORS; PROGNOSTIC-SIGNIFICANCE; DRUG-RESISTANCE; CLINICOPATHOLOGICAL SIGNIFICANCE},
   language = {eng},
   issn = {1932-6203},
   journal = {PLOS ONE},
   title = {Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis},
   volume = {9},
   year = {2014}
}

TY  - JOUR
ID  - 1187238
AU  - Gumulec, Jaromír - Raudenská, Martina - Adam, Vojtěch - Kizek, René - Masařík, Michal
PY  - 2014
TI  - Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis
JF  - PLOS ONE
VL  - 9
IS  - 1
SP  - "e85346"
EP  - "e85346"
PB  - PUBLIC LIBRARY SCIENCE
SN  - 19326203
KW  - SQUAMOUS-CELL CARCINOMA
KW  - PAPILLARY THYROID-CARCINOMA
KW  - PROSTATE-SPECIFIC ANTIGEN
KW  - PRIMARY BREAST CARCINOMAS
KW  - HUMAN BLADDER-CANCER
KW  - HEPATOCELLULAR-CARCINOMA
KW  - OVARIAN-TUMORS
KW  - PROGNOSTIC-SIGNIFICANCE
KW  - DRUG-RESISTANCE
KW  - CLINICOPATHOLOGICAL SIGNIFICANCE
N2  - Metallothionein (MT) has been extensively investigated as a molecular marker of various types of cancer. In spite of the fact that numerous reviews have been published in this field, no meta-analytical approach has been performed. Therefore, results of to-date immunohistochemistry-based studies were summarized using meta-analysis in this review. Web of science, PubMed, Embase and CENTRAL databases were searched (up to April 30, 2013) and the eligibility of individual studies and heterogeneity among the studies was assessed. Random and fixed effects model meta-analysis was employed depending on the heterogeneity, and publication bias was evaluated using funnel plots and Egger's tests. A total of 77 studies were included with 8,015 tissue samples (4,631 cases and 3,384 controls). A significantly positive association between MT staining and tumors (vs. healthy tissues) was observed in head and neck (odds ratio, OR 9.95; 95% CI 5.82-17.03) and ovarian tumors (OR 7.83; 1.09-56.29), and a negative association was ascertained in liver tumors (OR 0.10; 0.03-0.30). No significant associations were identified in breast, colorectal, prostate, thyroid, stomach, bladder, kidney, gallbladder, and uterine cancers and in melanoma. While no associations were identified between MT and tumor staging, a positive association was identified with the tumor grade (OR 1.58; 1.08-2.30). In particular, strong associations were observed in breast, ovarian, uterine and prostate cancers. Borderline significant association of metastatic status and MT staining were determined (OR 1.59; 1.03-2.46), particularly in esophageal cancer. Additionally, a significant association between the patient prognosis and MT staining was also demonstrated (hazard ratio 2.04; 1.47-2.81). However, a high degree of inconsistence was observed in several tumor types, including colorectal, kidney and prostate cancer. Despite the ambiguity in some tumor types, conclusive results are provided in the tumors of head and neck, ovary and liver and in relation to the tumor grade and patient survival.
ER  -

GUMULEC, Jaromír; Martina RAUDENSKÁ; Vojtěch ADAM; René KIZEK a Michal MASAŘÍK. Metallothionein - Immunohistochemical Cancer Biomarker: A Meta-Analysis. \textit{PLOS ONE}. USA: PUBLIC LIBRARY SCIENCE, 2014, roč.~9, č.~1, s.~''e85346'', 14 s. ISSN~1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0085346.

Přehled o publikaci